Drug Profile
Research programme: glutamate carboxypeptidase II inhibitors - Eisai
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Johns Hopkins Brain Science Institute; MGI GP
- Developer Eisai Co Ltd; Johns Hopkins Brain Science Institute
- Class Eye disorder therapies; Neuroprotectants
- Mechanism of Action Glutamate carboxypeptidase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders; Neurological disorders; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Eye-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
- 04 Nov 2017 No recent reports of development identified for research development in Neurological-disorders in USA